1. Medicines
  2. Oncology
  3. TAFINLAR® (dabrafenib) and MEKINIST® (trametinib)
  4. Metastatic treatment

Treatment of BRAF-positive metastatic melanoma

__________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________

Treatment of BRAF-positive metastatic melanoma

__________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________

Tafinlar (dabrafenib) in combination with Mekinist (trametinib) is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.1,2

Landmark data demonstrate Tafinlar + Mekinist achieves durable overall survival and long-term progression-free survival benefits versus BRAF inhibitor alone that are maintained over 5 years. Treatment with Tafinlar + Mekinist is also associated with an established safety profile.3

Please select an option below to find out more about patient management, or the efficacy and safety profile of Tafinlar + Mekinist for the treatment of BRAF-positive metastatic melanoma.

References

  1. Tafinlar (dabrafenib) Summary of Product Characteristics.
  2. Mekinist (trametinib) Summary of Product Characteristics.
  3. Robert C et al. N Engl J Med. 2019 Aug 15; 381:626–636.
Rate this content: 
No votes yet

Metastatic treatment – Efficacy

...Show more

Management of patients with BRAF positive melanoma

...Show more

IE 154649 November 2021
Oncology
Print
×

Ask Speakers

×

Medical Information Request

Reporting of side effects
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk profile of the medicinal product. All suspected adverse reactions should be reported to HPRA Pharmacovigilance, website www.hpra.ie. Adverse events can also be reported to Novartis preferably at www.novartis.com/report, by emailing [email protected] or by calling (01) 2080 612.